Compare FTK & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTK | ENTA |
|---|---|---|
| Founded | 1985 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 445.8M | 407.5M |
| IPO Year | N/A | 2013 |
| Metric | FTK | ENTA |
|---|---|---|
| Price | $14.04 | $13.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $16.00 | ★ $20.33 |
| AVG Volume (30 Days) | ★ 369.7K | 298.3K |
| Earning Date | 11-04-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 242.12 | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $220,501,000.00 | $65,324,000.00 |
| Revenue This Year | $19.47 | $2.13 |
| Revenue Next Year | $11.29 | $2.74 |
| P/E Ratio | $15.28 | ★ N/A |
| Revenue Growth | ★ 23.56 | N/A |
| 52 Week Low | $6.05 | $4.09 |
| 52 Week High | $18.96 | $15.34 |
| Indicator | FTK | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 70.25 |
| Support Level | $13.75 | $11.89 |
| Resistance Level | $14.67 | $14.51 |
| Average True Range (ATR) | 0.80 | 0.86 |
| MACD | -0.07 | 0.15 |
| Stochastic Oscillator | 34.00 | 80.34 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.